Dr. Kumar has been an investor, founder, director and CEO of several technology enterprises, both public and private. As CEO, he took CombiMatrix Corporation public and ran it for a decade while listed on the NASDAQ Global Market. He has worked in venture capital with OAK Investment Partners, and has ...
Dr. Baskies is a specialist in surgical oncology and general surgery, affiliated with Virtua Health Systems. He is former Chairman of the National Board of Directors of the American Cancer Society and current Chair of the society’s Global Cancer Control Advisory Council. He is a member of the Global Breast ...
Dr. Cullen is the Marlene and Stewart Greenebaum Distinguished Professor in Oncology and Director of the Program in Oncology at the UMSOM. He also serves as director of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center. In 2011, Dr. Cullen was appointed by President Obama to a ...
Dr. Goldberg is a longtime American Cancer Society and ACS Cancer Action Network volunteer. He has been a member of the ACS Eastern New England Board since 2017; and a member of the ACS national board of directors since 2019, serving as Board Scientific Officer since 2022. Dr. Goldberg currently ...
Mr. Heist has been the Director of Internal Audit at Penn State since 2003, bringing more than 30 years of auditing and accounting experience. He is active with the American Cancer Society, serving at the local, state, and national level; and is a past Chairman of the Board of the ...
Dr. Knudsen has been the CEO of the American Cancer Society and its advocacy affiliate, American Cancer Society Cancer Action Network, since 2021. She previously served as Executive Vice President of Oncology Services and Enterprise Director for Sidney Kimmel Cancer Center at Jefferson Health; President for the Association of American ...
Dr. Lichtenfeld is an experienced medical oncologist and independent consultant with an extensive background in cancer care, cancer research, healthcare policy, and physician payment. He is a member of the CancerCare board of directors, and an advisor to several early-stage patient- and cancer-focused companies, including Trialjectory and OneHealth. Dr. Lichtenfeld ...
Mr. Marquardt is the CEO of Global Kompass Strategies, serving as a global advisor to corporations around the world; and CEO of Epi One, a biotech company building a new cancer diagnosis platform. He previously led several companies in the technology and healthcare sectors, and served as President of the ...
Ms. Mueller currently serves on the board of the American Cancer Society Cancer Action Network. She has volunteered with the American Cancer Society for more than 35 years and has held numerous committee and leadership positions, including board President/Chair of the former Florida Division and Chair of the American Cancer ...
Mr. Reedy was CEO of the American Cancer Society and American Cancer Society Cancer Action Network from 2015 to 2021, following 15 years of volunteer leadership, including chairing the boards of directors for the organizations. He previously served as Worldwide Vice President, Government Affairs and Policy at Johnson & Johnson, ...
Mr. Youle is a civil practice attorney based in Denver, Colorado. He was a volunteer for the American Cancer Society for nearly 30 years, serving at the local, state, regional and national levels. Mr. Youle served as Chairman of the Board of the American Cancer Society’s former Colorado and Rocky ...
Dr. Sanjay Juneja is a board-certified hematologist and medical oncologist currently practicing in Baton Rouge, Louisiana. He is the host of the internationally engaged 'Target: Cancer Podcast, ' and carries over one-half million followers through his media brand 'TheOncDoc.'
Dr. Juneja served on the White House Leaders in Social Media ...
Latest News & Events
Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial
Read More...Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Read More...Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Read More...